ADCendo - Gilde Healthcare


Copenhagen, Denmark
Antibody Drug Conjugates (ADCs)
Since: 2021

Danish Therapeutics company focused on antibody-drug conjugates (ADCs) for the treatment of cancers.

ADCs are a class of highly potent biopharmaceutical drugs, composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. ADCs combine the unique and very sensitive targeting capabilities of antibodies, with the potent effects of the conjugated cytotoxic drugs, allowing sensitive discrimination between healthy and cancer tissues. ADCendo raised a €51 million ($62 million) Series A financing to establish a pipeline of ADCs directed at novel cancer targets and to bring the lead program targeting the novel cancer target uPARAP/Endo180 to proof of concept in soft tissue sarcoma patients.

More ADCendo news

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare company ADCendo appoints Dominik Mumberg, PHD, as Chief Scientific Officer

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Gilde Healthcare portfolio company ADCendo appoints Michael Pehl as Chief Executive Officer

Gilde Healthcare participates in €51M series A financing of Danish biopharmaceutical start-up ADCendo